Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
GlaxoSmithKline
>
An honest insider post, the REAL future at GSK.....
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 1969659"]Using multiple layoffs to keep overall layoff costs down is absolutely an effective and jaded way to lower costs, with the bonus of multiple layoff bumps from Wall Street. </p><p><br /></p><p>I am sure that many people will bail if they make it past the first cut. I also anticipate a more zealous PIP/sample audit/expense audit strategy going forward to both weed out 'undesirables' and encourage voluntary departures. </p><p><br /></p><p>From a personnel standpoint, this strategy will backfire just as it did with Pfizer. There are still many great reps with Pfizer, but most of the ones I know who have stayed are tenured and don't want to walk away from their retirement package or they are too lazy to look for something new. The good Pfizer reps who had 3-6 years experience have all left or are interviewing.</p><p><br /></p><p>GSK will end up weeding out the reps it does not want to lose. The high performers are the most employable and they know it. If the BS becomes too much, the goals too high and the environment too hostile, the good reps will leave. Just like Pfizer, the reps who stay will be the ones who stay because they are close to retirement or they can not find anything else.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 1969659"]Using multiple layoffs to keep overall layoff costs down is absolutely an effective and jaded way to lower costs, with the bonus of multiple layoff bumps from Wall Street. I am sure that many people will bail if they make it past the first cut. I also anticipate a more zealous PIP/sample audit/expense audit strategy going forward to both weed out 'undesirables' and encourage voluntary departures. From a personnel standpoint, this strategy will backfire just as it did with Pfizer. There are still many great reps with Pfizer, but most of the ones I know who have stayed are tenured and don't want to walk away from their retirement package or they are too lazy to look for something new. The good Pfizer reps who had 3-6 years experience have all left or are interviewing. GSK will end up weeding out the reps it does not want to lose. The high performers are the most employable and they know it. If the BS becomes too much, the goals too high and the environment too hostile, the good reps will leave. Just like Pfizer, the reps who stay will be the ones who stay because they are close to retirement or they can not find anything else.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
GlaxoSmithKline
>
An honest insider post, the REAL future at GSK.....
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
GlaxoSmithKline
>
An honest insider post, the REAL future at GSK.....
>